Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · AARTIPHARM

AARTIPHARM

HealthcarePharmaceuticals & Biotechnology₹9173 cr market cap
₹1013.90 ▲ +0.05% today As of 19 Nov 2026
52-week low ₹591.9552-week high ₹1015.90

-0.2% from the 52-week high · +71.2% above the low

Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.

The short version. AARTIPHARM reported revenue of ₹610 crore for Sep 2026, up 45.9% from a year earlier. Net profit was ₹71 crore (up 144.8% year on year). Return on equity was 8.2% in Mar 2026. Promoter holding was 39.66% in Sep 2026, down 4.99 points over 8 quarters.

1 · The price

How has the stock traded?

AARTIPHARM trades 0.2% below its 52-week high and 71.2% above its 52-week low.

Change over period: —

1M+21.8%
3M+21.5%
6M+44.6%
1Y+42.3%

2 · The business

Is it growing?

Sales, year on year+45.9%

Sep 2026 revenue of ₹610 cr.

Profit, year on year+144.8%

Sep 2026 net profit of ₹71 cr.

Net margin11.7%

4.9 pts higher than a year earlier.

3-year growth-3.4% profit

Revenue compounded at -2.1% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue610536583432418386564538
Net profit7176614829508874
Net margin %11.714.210.511.16.812.815.713.8
EPS (₹)7.888.46.745.293.155.469.758.16

Annual

FY2026FY2025FY2024FY2023
Revenue1819211518531945
Net profit175272216193
Net margin %9.612.911.79.9
EPS (₹)19.2730.0623.8821.35

3 · The quality

How well does it turn capital into profit?

Return on equity was 8.2% in Mar 2026; debt to equity is 0.32.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %8.213.712.312.4
Return on capital %10.717.216.817.2
EBITDA margin %20.622.321.117.7
Net margin %9.612.811.79.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-2.1%—
Profit CAGR-3.4%—
Debt to equity0.32
Interest cover5.8x
Current ratio1.49
P/E ratio37.9

4 · The owners

Who holds it, and are they adding?

Promoter holding39.66%

Down 4.99 pts over 8 quarters.

Foreign institutions8.15%

Down 0.49 pts over 8 quarters.

Domestic institutions8.4%

Down 1.96 pts over 8 quarters.

Mutual fund schemes17

+7 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter44.6544.2943.7242.8843.143.0842.8639.66-4.99
FII8.647.367.358.027.688.398.178.15-0.49
DII10.367.537.796.967.667.417.228.4-1.96
Public36.3340.8141.1242.1341.5441.1141.7443.78+7.45

Mutual fund holdings · Oct 2026

17 schemes hold this stock

10 the month before.

  • Unifi Flexi Cap Fund3.11% of NAV
  • UNION ACTIVE MOMENTUM FUND1.82% of NAV
  • WhiteOak Capital Pharma and Healthcare Fund1.06% of NAV
  • UTI - Healthcare Fund0.91% of NAV
  • Motilal Oswal Nifty Microcap 250 Index Fund0.55% of NAV
  • Taurus Flexi Cap Fund0.54% of NAV
  • Motilal Oswal BSE Healthcare ETF0.28% of NAV
  • Bandhan BSE Healthcare Index Fund0.28% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for AARTIPHARM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about AARTIPHARM

What is the AARTIPHARM share price?

AARTIPHARM (AARTIPHARM) last closed at ₹1,013.90, up 0.05% on the day. Its 52-week range is ₹591.95 to ₹1,015.90.

What is the market cap of AARTIPHARM?

AARTIPHARM has a market capitalisation of about ₹9,173 crore. Its price-to-earnings ratio is 37.9.

How are AARTIPHARM's latest results?

AARTIPHARM reported revenue of ₹610 crore for Sep 2026, up 45.9% from a year earlier. Net profit was ₹71 crore (up 144.8% year on year). Return on equity was 8.2% in Mar 2026. Promoter holding was 39.66% in Sep 2026, down 4.99 points over 8 quarters.

Who owns AARTIPHARM?

As of Sep 2026, shareholding was: Promoter 39.66%, FII 8.15%, DII 8.4%, Public 43.78%.

How many mutual funds hold AARTIPHARM?

17 mutual fund schemes held AARTIPHARM in October 2026. That compares with 10 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 16 Feb 2026 · Interim Dividend - Rs. 1.5
  • 15 Sep 2025 · Final Dividend - Rs. 2.5
  • 14 Feb 2025 · Interim Dividend - Rs. 2.5
  • 31 Jul 2024 · Final Dividend - Rs. 1
  • 16 Feb 2024 · Interim Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.